4MZK
| Crystal Structure of MTIP from Plasmodium falciparum in complex with pGly[807,811], a stapled myoA tail peptide | Descriptor: | Myosin A tail domain interacting protein, pGly[807,811], a stapled myoA tail peptide | Authors: | Douse, C.H, Garnett, J.A, Maas, S.J, Cota, E, Tate, E.W. | Deposit date: | 2013-09-30 | Release date: | 2013-11-06 | Last modified: | 2023-12-06 | Method: | X-RAY DIFFRACTION (1.82 Å) | Cite: | Crystal Structures of Stapled and Hydrogen Bond Surrogate Peptides Targeting a Fully Buried Protein-Helix Interaction. Acs Chem.Biol., 8, 2014
|
|
5T92
| ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3-{4-[(1R)-2-(4-fluorophenyl)-6-hydroxy-1-methy l-1,2,3,4- tetrahydroisoquinolin-1-yl]phenyl}prop-2-enoic acid | Descriptor: | (2E)-3-{4-[(1R)-2-(4-fluorophenyl)-6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]phenyl}prop-2-enoic acid, Estrogen receptor | Authors: | Kirby, C, Baird, J. | Deposit date: | 2016-09-09 | Release date: | 2017-03-29 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.22 Å) | Cite: | Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ER alpha + Breast Cancer. J. Med. Chem., 60, 2017
|
|
5T97
| ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3-(4-{(1R)-6-hydroxy-1-methyl-2-[4-(propan-2 -yl)phenyl]-1,2,3,4- tetrahydroisoquinolin-1-yl}phenyl)prop-2-enoic acid | Descriptor: | (2E)-3-(4-{(1R)-6-hydroxy-1-methyl-2-[4-(propan-2-yl)phenyl]-1,2,3,4-tetrahydroisoquinolin-1-yl}phenyl)prop-2-enoic acid, Estrogen receptor | Authors: | Kirby, C.A, Baird, J. | Deposit date: | 2016-09-09 | Release date: | 2017-03-29 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (3 Å) | Cite: | Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ER alpha + Breast Cancer. J. Med. Chem., 60, 2017
|
|
7YYO
| Cryo-EM structure of an a-carboxysome RuBisCO enzyme at 2.9 A resolution | Descriptor: | 2-CARBOXYARABINITOL-1,5-DIPHOSPHATE, MAGNESIUM ION, Ribulose bisphosphate carboxylase large chain, ... | Authors: | Mann, D, Evans, S.L, Bergeron, J.R.C. | Deposit date: | 2022-02-18 | Release date: | 2023-01-25 | Last modified: | 2023-06-14 | Method: | ELECTRON MICROSCOPY (2.87 Å) | Cite: | Single-particle cryo-EM analysis of the shell architecture and internal organization of an intact alpha-carboxysome. Structure, 31, 2023
|
|
7BUY
| The crystal structure of COVID-19 main protease in complex with carmofur | Descriptor: | 3C-like proteinase, DIMETHYL SULFOXIDE, hexylcarbamic acid | Authors: | Zhao, Y, Zhang, B, Jin, Z, Liu, X, Yang, H, Rao, Z. | Deposit date: | 2020-04-08 | Release date: | 2020-04-29 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat.Struct.Mol.Biol., 27, 2020
|
|
2J3E
| Dimerization is important for the GTPase activity of chloroplast translocon components atToc33 and psToc159 | Descriptor: | GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, T7I23.11 PROTEIN | Authors: | Yeh, Y.-H, Kesavulu, M.M, Wu, S.-Z, Li, H.-M, Sun, Y.-J, Konozy, E.H, Hsiao, C.-D. | Deposit date: | 2006-08-21 | Release date: | 2007-03-27 | Last modified: | 2023-12-13 | Method: | X-RAY DIFFRACTION (3.2 Å) | Cite: | Dimerization is Important for the Gtpase Activity of Chloroplast Translocon Components Attoc33 and Pstoc159. J.Biol.Chem., 282, 2007
|
|
3EFK
| Structure of c-Met with pyrimidone inhibitor 50 | Descriptor: | 5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-2-[(4-fluorophenyl)amino]-3-methylpyrimidin-4(3H)-one, Hepatocyte growth factor receptor | Authors: | Bellon, S.F, D'Angelo, N, Whittington, D, Dussault, I. | Deposit date: | 2008-09-09 | Release date: | 2008-10-07 | Last modified: | 2023-08-30 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Design, synthesis, and biological evaluation of potent c-Met inhibitors. J.Med.Chem., 51, 2008
|
|
3EFJ
| Structure of c-Met with pyrimidone inhibitor 7 | Descriptor: | 2-benzyl-5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-3-methylpyrimidin-4(3H)-one, Hepatocyte growth factor receptor | Authors: | D'Angelo, N, Bellon, S, Whittington, D. | Deposit date: | 2008-09-09 | Release date: | 2008-10-07 | Last modified: | 2023-08-30 | Method: | X-RAY DIFFRACTION (2.6 Å) | Cite: | Design, synthesis, and biological evaluation of potent c-Met inhibitors. J.Med.Chem., 51, 2008
|
|
7QK4
| EED in complex with PRC2 allosteric inhibitor compound 22 (MAK683) | Descriptor: | CHLORIDE ION, Histone-lysine N-methyltransferase EZH2, N-[(5-fluoranyl-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, ... | Authors: | Zhao, K, Zhao, M, Luo, X, Zhang, H, Scheufler, C. | Deposit date: | 2021-12-17 | Release date: | 2022-04-13 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (1.602 Å) | Cite: | Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. J.Med.Chem., 65, 2022
|
|
7QJG
| EED in complex with PRC2 allosteric inhibitor compound 6 | Descriptor: | CHLORIDE ION, Histone-lysine N-methyltransferase EZH2, N-(2,3-dihydro-1-benzofuran-7-ylmethyl)-8-[4-[(dimethylamino)methyl]phenyl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, ... | Authors: | Zhao, K, Zhao, M, Luo, X, Zhang, H, Scheufler, C. | Deposit date: | 2021-12-16 | Release date: | 2022-04-13 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. J.Med.Chem., 65, 2022
|
|
7QJU
| EED in complex with PRC2 allosteric inhibitor compound 7 | Descriptor: | CHLORIDE ION, Histone-lysine N-methyltransferase EZH2, N-(2,3-dihydro-1-benzofuran-4-ylmethyl)-8-[4-[(dimethylamino)methyl]phenyl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, ... | Authors: | Zhao, K, Zhao, M, Luo, X, Zhang, H, Scheufler, C. | Deposit date: | 2021-12-17 | Release date: | 2022-04-13 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. J.Med.Chem., 65, 2022
|
|
8H03
| |
8H04
| |
8H05
| |
8HR2
| Ternary Crystal Complex Structure of RBD with NB1B5 and NB1C6 | Descriptor: | NB1B5, NB1C6, Spike protein S1 | Authors: | Sun, Z. | Deposit date: | 2022-12-14 | Release date: | 2023-08-16 | Method: | X-RAY DIFFRACTION (1.94 Å) | Cite: | Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes. J.Struct.Biol., 215, 2023
|
|
8VYG
| SARS-CoV-2 S RBD (C.37 Lambda variant) plus S309 Fab, local refinement | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, S309 Heavy Chain, S309 Light Chain, ... | Authors: | McCallum, M, Veesler, D, Seattle Structural Genomics Center for Infectious Disease (SSGCID) | Deposit date: | 2024-02-08 | Release date: | 2024-03-27 | Method: | ELECTRON MICROSCOPY (3.1 Å) | Cite: | Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features. Nat Commun, 15, 2024
|
|
8VYE
| SARS-CoV-2 S (C.37 Lambda variant) plus S309, S2L20, and S2X303 Fabs | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, S2L20 Heavy Chain, S2L20 Light Chain, ... | Authors: | McCallum, M, Veesler, D, Seattle Structural Genomics Center for Infectious Disease (SSGCID) | Deposit date: | 2024-02-08 | Release date: | 2024-03-27 | Method: | ELECTRON MICROSCOPY (2.7 Å) | Cite: | Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features. Nat Commun, 15, 2024
|
|
8VYF
| SARS-CoV-2 S NTD (C.37 Lambda variant) plus S2L20 and S2X303 Fabs, local refinement | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, S2L20 Heavy Chain, ... | Authors: | McCallum, M, Veesler, D, Seattle Structural Genomics Center for Infectious Disease (SSGCID) | Deposit date: | 2024-02-08 | Release date: | 2024-03-27 | Method: | ELECTRON MICROSCOPY (3.2 Å) | Cite: | Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features. Nat Commun, 15, 2024
|
|
8T5C
| Lassa GPC Trimer in complex with Fab 8.11G and nanobody D5 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 8.11G Heavy Chain, 8.11G Light Chain, ... | Authors: | Gorman, J, Kwong, P.D. | Deposit date: | 2023-06-13 | Release date: | 2024-01-03 | Last modified: | 2024-01-24 | Method: | ELECTRON MICROSCOPY (4.7 Å) | Cite: | Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nat Commun, 15, 2024
|
|
5HYW
| The crystal structure of the D3-ASK1 complex | Descriptor: | F-box/LRR-repeat MAX2 homolog, SKP1-like protein 1A | Authors: | Yao, R.F, Ming, Z.H, Yan, L.M, Rao, Z.H, Lou, Z.Y, Xie, D.X. | Deposit date: | 2016-02-02 | Release date: | 2016-08-03 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (3.01 Å) | Cite: | DWARF14 is a non-canonical hormone receptor for strigolactone Nature, 536, 2016
|
|
7URC
| Human PORCN in complex with LGK974 | Descriptor: | 2-[(2P)-2',3-dimethyl[2,4'-bipyridin]-5-yl]-N-[(5P)-5-(pyrazin-2-yl)pyridin-2-yl]acetamide, 2C11 heavy chain, 2C11 light chain, ... | Authors: | Liu, Y, Qi, X, Li, X. | Deposit date: | 2022-04-21 | Release date: | 2022-07-20 | Last modified: | 2022-08-10 | Method: | ELECTRON MICROSCOPY (3.14 Å) | Cite: | Mechanisms and inhibition of Porcupine-mediated Wnt acylation. Nature, 607, 2022
|
|
7URE
| Human PORCN in complex with palmitoleoylated WNT3A peptide | Descriptor: | 2C11 heavy chain, 2C11 light chain, Digitonin, ... | Authors: | Liu, Y, Qi, X, Li, X. | Deposit date: | 2022-04-21 | Release date: | 2022-07-20 | Last modified: | 2022-08-10 | Method: | ELECTRON MICROSCOPY (3.19 Å) | Cite: | Mechanisms and inhibition of Porcupine-mediated Wnt acylation. Nature, 607, 2022
|
|
7URD
| Human PORCN in complex with LGK974 and WNT3A peptide | Descriptor: | 2-[(2P)-2',3-dimethyl[2,4'-bipyridin]-5-yl]-N-[(5P)-5-(pyrazin-2-yl)pyridin-2-yl]acetamide, 2C11 heavy chain, 2C11 light chain, ... | Authors: | Liu, Y, Qi, X, Li, X. | Deposit date: | 2022-04-21 | Release date: | 2022-07-20 | Last modified: | 2022-08-10 | Method: | ELECTRON MICROSCOPY (2.92 Å) | Cite: | Mechanisms and inhibition of Porcupine-mediated Wnt acylation. Nature, 607, 2022
|
|
7URA
| Human PORCN in complex with Palmitoleoyl-CoA | Descriptor: | 2C11 heavy chain, 2C11 light chain, CHOLESTEROL, ... | Authors: | Liu, Y, Qi, X, Li, X. | Deposit date: | 2022-04-21 | Release date: | 2022-07-20 | Last modified: | 2022-08-10 | Method: | ELECTRON MICROSCOPY (3.11 Å) | Cite: | Mechanisms and inhibition of Porcupine-mediated Wnt acylation. Nature, 607, 2022
|
|
7URF
| Human HHAT H379C in complex with SHH N-terminal peptide | Descriptor: | 3H02 heavy chain, 3H02 light chain, Digitonin, ... | Authors: | Liu, Y, Qi, X, Li, X. | Deposit date: | 2022-04-21 | Release date: | 2022-07-20 | Last modified: | 2022-08-10 | Method: | ELECTRON MICROSCOPY (2.8 Å) | Cite: | Mechanisms and inhibition of Porcupine-mediated Wnt acylation. Nature, 607, 2022
|
|